Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/3/2026

1. PANW
2. GTLB
3. DELL
4. MDB
5. GOOGL

6. VRTS
7. SPY
8. HPE
9. USO
10. SNOW

Get Alerts ZNTL Hot Sheet

Price: $3.77 +1.62%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences.

Presentation Details:

Event: Guggenheim Healthcare Talks | Oncology DayDate/Time: Wednesday, February 8th, 2023 at 9:00 a.m. ETLocation: New York City

Event: SVB Securities Global Biopharma ConferenceDate/Time: Tuesday, February 14th, 2023 at 3:00 p.m. ETLocation: Virtual

Webcasts will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website.

About Zentalis PharmaceuticalsZentalis™ Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Utilizing its Integrated Discovery Engine, the Company is developing a focused pipeline of potentially best-in-class oncology candidates, which include azenosertib (ZN-c3), a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Investor Contacts:

Adam D. Levy, PhD, MBASenior Vice President, Investor Relations[email protected]

Alexandra RoySolebury Strategic Communications[email protected]

Media Contact:

Julia DeutschSolebury Strategic Communications[email protected]